NY-ESO-1 Peptide (157-165)
The New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide (157-165, SLLMWITQV) is a peptide corresponding to NY-ESO-1 amino acids 157-165, in which the naturally occurring cysteine (C) at the C-terminus is mutated to Valine (V) to prevent the formation of disulfide bonds. The NY-ESO-1 peptide is widely used to stimulate human NY-ESO-1-specific CD8+ T cells.
1 mM peptide in DMSO
NY-ESO-1 (also known as Cancer testis antigen 1, or CTAG1B), is an important tumorigenic marke present in malignant cells. Normally expressed only in embryonic testis, this highly immunogenic protein is not usually found in normal tissues, but re-expressed in multiple myeloma, non-small cell lung carcinoma and, breast and ovarian cancer, making it a promising candidate antigen for cancer immunotherapy. Several NY-ESO-1 directed therapies are being developed including cancer vaccines, anti-NY-ESO-1 adoptive cell therapy, and NY-ESO-1-specific TCR-T cell therapy in combination with checkpoint inhibitors.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.